7Baggers

Cellectis S.A
(NASDAQ:CLLS) 

CLLS stock logo

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an all...

Founded: 1999
Full Time Employees: 253
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2025-11-07 2025-08-04 2025-05-12 2024-11-04 2024-08-06 2023-08-07 2023-05-04 2023-03-08 2023-03-06 2022-11-03 2022-08-04 2022-05-12 2022-05-05 2022-03-03 2021-12-31 2021-11-04 2021-08-05 2021-06-30 2021-05-06 2021-03-04 2020-12-31 2020-11-05 2020-08-05 2020-05-06 2020-03-04 2019-12-31 2019-11-06 2019-09-30 2019-08-06 2019-05-07 2019-03-11 2018-12-31 2018-11-13 2018-08-01 2018-05-07 2018-03-12 2017-12-31 2017-11-13 2017-09-01 2017-08-02 2017-05-09 2017-03-06 2016-12-31 2016-11-22 2016-09-08 2016-05-11 2016-03-14 2015-12-31 2015-11-16 2015-09-08 2015-06-09 
                                                       
      revenues and other income
    		                                                   
      revenues
    		35,172,000 27,380,000 10,655,000 28,789,000 12,589,000 317,000 139,000 16,024,000  3,262,000 3,045,000 1,697,000  13,649,000  8,312,000 11,176,000 36,777,000 25,601,000 13,649,000  6,179,000 2,900,000 50,128,000 15,000  10,000  1,000 1,000 968,000 2,750 906,000 5,000 6,000 5,000 4,750 6,000  5,902,000 6,000 7,000 8,000 10,000 15,000 6,000 26,000  7,000 7,328 8,428,000 
      other income
    		1,992,000 2,842,000 1,373,000 5,263,000 3,412,000 5,242,000 3,420,000 1,298,000  5,255,000 3,551,000 2,135,000  1,983,000  2,516,000 3,439,000 5,804,000 2,365,000 1,983,000  3,063,000 1,716,000 1,778,000 7,000  5,000  1,000 2,000 2,000 1,500 1,000 3,000 2,000 1,000 1,750 1,000  2,248,000 3,000 4,000 1,500 1,000 2,000 2,000 2,000  2,000 676,000 791,000 
      total revenues and other income
    		37,164,000 30,222,000 12,029,000 34,052,000 16,002,000 5,560,000 3,559,000 17,322,000  8,517,000 6,596,000 3,832,000  15,632,000  10,827,000 14,615,000 42,581,000 27,966,000 15,632,000  9,242,000 4,616,000 51,907,000 22,000  16,000  2,000 3,000 3,000 4,500 2,000 8,000 8,000 6,000 6,500 7,000  8,150,000 9,000 12,000 9,500 11,000 18,000 9,000 29,000  9,000 8,004 9,219,000 
      operating expenses
    		                                                   
      research and development expenses
    		-24,069,000 -45,012,000 -21,932,000 -69,670,000 -45,841,000 -43,225,000 -21,081,000 -21,433,000  -85,194,000 -58,527,000 -29,479,000  -23,395,000  -34,324,000 -31,147,000 -62,338,000  -23,395,000  -20,103,000   -92,000  -61,000  -25,000 -14,000 -21,000 -21,567 -18,000 -18,000 -18,000 -20,000 -79,169,000 -20,000 -2,215,000 -16,910,000 -18,000 -18,000 -70,847,000 -13,000 -19,000 -18,000 -16,000  -13,000 -10,565 -5,600,000 
      selling, general and administrative expenses
    		-5,208,000 -9,780,000 -4,702,000 -14,153,000 -8,986,000 -8,914,000 -4,964,000 -1,698,000  -25,336,000 -17,695,000 -9,279,000  -12,490,000  -9,675,000 -9,343,000 -18,219,000  -12,490,000  -10,301,000   -43,000  -34,000  -11,000 -11,000 -10,000 -11,248 -11,000 -11,000 -14,000 -12,000 -44,719,000 -12,000 -3,529,000 -9,105,000 -9,000 -11,000 -39,203,000 -8,000 -8,000 -10,000 -8,000  -9,000 -9,082 -7,195,000 
      other operating income
    		154,000 804,000 426,000 896,000 721,000 -83,000 -611,000 839,000  608,000 1,016,000 65,000  -267,000  18,000 150,000 488,000 56,000 -267,000  -374,000 111,000  -91,000     33,000 162,000 -34,500 30,000 -189,000 21,000       -39,000 -35,000  264,000 122,000 297,000   166,000 350,000 
      total operating expenses
    		-29,123,000   -82,926,000 -54,107,000 -52,612,000 -26,990,000 -22,982,000 3,355,000 -111,003,000 -75,920,000 -39,078,000 6,121,000 -54,796,000  -53,195,000 -52,096,000 -99,968,000  -54,796,000  -38,595,000   -146,000  -101,000  -38,000 -26,000 -32,000 -23,500 -31,000 -30,000 -32,000 -34,000 -22,750 -32,000 -5,813,000 -26,190,000 -28,000 -30,000          
      operating income
    		8,041,000 -23,766,000 -14,179,000 -48,874,000 -38,105,000 -47,053,000 -23,431,000 -5,660,000  -102,485,000 -69,324,000 -35,247,000  -39,164,000  -42,368,000 -37,481,000 -57,387,000  -39,164,000  -29,353,000  14,412,000 -123,000  -84,000  -35,000 -23,000 -29,000 -51,523 -28,000 -21,000 -24,000 -27,000 -92,585,000 -25,000  -18,040,000 -18,000 -18,000 -60,777,000 -11,000 -10,000 -20,000 1,000  -13,000 -12,126 -3,558,000 
      yoy
    		-121.10% -49.49% -39.49% 763.50%  -54.09% -66.20% -83.94%  161.68%  -16.81%  -31.75%  8.18%  95.51%  -371.75%     251.43%  189.66%  25.00% 9.52% 20.83% 90.83% -99.97% -16.00%  -99.85% 514261.11% 38.89%  163900.00% 80.00% -10.00% -6077800.00%  -23.08% 64.93% -100.03%     
      qoq
    		-133.83% 67.61% -70.99% 28.26% -19.02% 100.82% 313.98%   47.83% 96.68%     13.04% -34.69%       -11817.07%     52.17% -20.69% -43.71% 84.01% 33.33% -12.50% -11.11% -99.97% 370240.00%   100122.22% 0.00% -99.97% 552418.18% 10.00% -50.00% -2100.00%   7.21% -99.66%  
      operating margin %
    		Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% 0% -Infinity% -Infinity% -Infinity% 0% -Infinity% NaN% -Infinity% -Infinity% -Infinity% NaN% -Infinity% NaN% -Infinity% NaN% Infinity% -Infinity% NaN% -Infinity% NaN% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% NaN% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% NaN% -Infinity% -Infinity% -Infinity% 
      financial income
    		3,459,000 11,578,000 6,298,000 29,727,000 29,407,000 33,041,000 775,000                                             
      financial expenses
    		-10,912,000 -29,675,000 -10,246,000 -24,049,000 -11,384,000 -21,461,000 -5,177,000                                             
      net financial gain
    		-7,452,000 -18,098,000 -3,948,000 5,677,000 18,023,000 11,580,000 -4,402,000   17,009,000 15,113,000 490,000      431,000                                  
      income tax
    		   514,000 455,000 -258,000  -87,000                                            
      net income
    		589,000 -41,863,000 -18,128,000 -42,683,000 -19,627,000 -46,108,000 -32,525,000 -28,559,000  -85,476,000 -54,211,000 -34,757,000 -5,619,000 -46,730,000  -40,071,000 -41,610,000 -56,956,000  -46,730,000  -33,602,000  16,602,000 -115,000  -73,000  -36,000 -17,000 -26,000 -26,333 -25,000 -9,000 -27,000 -28,000 -103,608,000 -29,000 -5,604,000 -24,085,000 -18,000 -12,000 -60,728,000 -12,000 -6,000 -29,000 8,000  -12,000 -22,166 6,316,000 
      yoy
    		-103.00% -9.21% -44.26% 49.46%  -46.06% -40.00% -17.83%  82.91%  -13.26% -86.50% -17.95%  -14.25%  69.50%  -381.47%     219.44%  180.77%  44.00% 88.89% -3.70% -5.95% -99.98% -68.97% -99.52% -99.88% 575500.00% 141.67% -90.77% 200608.33% 200.00% -58.62% -759200.00%  -50.00% 30.83% -99.87%     
      qoq
    		-101.41% 130.93% -57.53% 117.47% -57.43% 41.76% 13.89%   57.67% 55.97% 518.56% -87.98%   -3.70% -26.94%       -14536.52%     111.76% -34.62% -1.26% 5.33% 177.78% -66.67% -3.57% -99.97% 357168.97% -99.48% -76.73% 133705.56% 50.00% -99.98% 505966.67% 100.00% -79.31% -462.50%   -45.86% -100.35%  
      net income margin %
    		Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% 0% -Infinity% -Infinity% -Infinity% -17559.38% -Infinity% NaN% -Infinity% -Infinity% -Infinity% NaN% -Infinity% NaN% -Infinity% NaN% Infinity% -Infinity% NaN% -Infinity% NaN% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% NaN% -Infinity% -Infinity% Infinity% 
      attributable to shareholders of cellectis
    		589,000 -41,863,000 -18,128,000 -42,683,000 -19,627,000 -40,715,000 -30,074,000 -26,815,000  -79,326,000 -50,858,000 -31,911,000  -40,607,000  -37,413,000 -39,919,000 -51,787,000  -40,607,000  -30,297,000  20,081,000 -102,000  -64,000  -33,000 -15,000 -23,000 -23,693 -22,000 -7,000 -25,000 -27,000 -18,000 -26,000  -24,085,000 -18,000 -12,000 -60,728,000 -12,000 -6,000 -29,000 8,000  -12,000 -22,166 6,146,000 
      basic / diluted net income per share attributable to shareholders of cellectis
    		                                                   
      basic net income attributable to shareholders of cellectis, per share
    		0.01 -0.42 -0.18 -0.49 -0.24                                               
      diluted net income attributable to shareholders of cellectis, per share
    		0.01 -0.42 -0.18 -0.49 -0.24                                               
      total operating expenses and other operating income
    		 -53,988,000 -26,208,000                                        -20,000 -22,000 -28,000 -29,000 -27,000  -23,000 -20,130 -12,777,000 
      actuarial gains and losses
    		  56                                                 
      currency translation adjustment generated by the parent company
    		  5,317                                                 
      other comprehensive income that will not be reclassified subsequently to income or loss from continued operations
    		  5,374                                                 
      currency translation adjustment
    		  -3,051                                                 
      other comprehensive income that will be reclassified subsequently to income or loss from continuing operations
    		  -3,051                                                 
      total other comprehensive income
    		  2,323                                                 
      total comprehensive income
    		  -15,805                                                 
      income from continuing operations
    		   -42,683,000 -19,627,000 -35,731,000 -27,833,000 -25,702,000                                   -12,000 -12,000  -29,000 8,000  -12,000 -22,166  
      income from discontinued operations
    		     -10,377,000 -4,691,000 -2,857,000                                            
      attributable to non-controlling interests
    		     -5,393,000 -2,450,000 -1,744,000  -6,150,000 -3,352,000 -2,846,000  -6,123,000  -2,658,000 -1,691,000 -5,169,000  -6,123,000  -3,305,000   -13,000  -9,000  -3,000 -2,000 -2,000 -3,640 -2,000 -2,000 -1,000 -1,000 -500 -2,000             171,000 
      basic net income attributable to shareholders of cellectis from discontinued operations, per share
    		                                                   
      diluted net income attributable to shareholders of cellectis from discontinued operations, per share
    		                                                   
      number of shares used for computing
    		                                                   
      basic
    		   87,355,605 80,881,026                                          35     
      diluted
    		   87,355,605 80,881,026                                          35     
      cost of revenue
    		     -389,000 -334,000 -690,000  -1,081,000 -714,000 -385,000  -18,644,000  -9,213,000 -11,754,000 -19,899,000  -18,644,000  -7,820,000   -11,000  -5,000  -815,000 -586,000                      
      basic net income attributable to shareholders of cellectis per share
    		     -0.76 -0.58 -0.59  -1.74 -1.12 -0.7  -0.95  -0.82 -0.88 -1.17  -0.95  -0.71  0.47 -2.41  -1.52  -0.79 -0.36 -53 -0.345 -0.54 -0.17 -0.71 -0.76 -0.508 -0.73  -0.68            
      diluted net income attributable to shareholders of cellectis per share
    		     -0.76 -0.58 -0.59  -1.74 -1.12 -0.7  -0.95  -0.82 -0.88 -1.17  -0.95  -0.71  0.47 -2.41  -1.52  -0.79 -0.36 -53 -0.345 -0.54 -0.17 -0.71 -0.76 -0.508 -0.73  -0.68            
      basic net income attributable to shareholders of cellectis per share ( /share) from discontinued operations
    		     -0.09 -0.04                                             
      diluted net income attributable to shareholders of cellectis per share ( /share) from discontinued operations
    		     -0.09 -0.04                                             
      financial gain
    		       -19,955,000      -7,567,000  2,296,000 -4,129,000  4,561,000 -7,567,000  -4,250,000  2,190,000 8,000  11,000  -1,000 5,000 3,000 3,758 3,000 11,000 -2,000 -958,000 -11,023,000 -3,000 -163,000 -6,045,000 -21,000 6,000 48,000 -1,000 3,000 -9,000 7,000  680,000 -10,039 9,874,000 
      basic net income attributable to shareholders of cellectis per share (/share) from discontinued operations
    		       -0.02                                            
      diluted net income attributable to shareholders of cellectis per share (/share) from discontinued operations
    		       -0.02                                            
      revenue
    		        42,000    32,000                                       
      yoy
    		        31.25%                                           
      qoq
    		                                                   
      cost of goods sold
    		                                                   
      gross profit
    		        42,000    32,000                                       
      yoy
    		        31.25%                                           
      qoq
    		                                                   
      gross margin %
    		NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% 100.00% NaN% NaN% NaN% 100.00% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% 
      operating expenses:
    		                                                   
      research and development
    		        2,346,000    2,941,000                                       
      selling, general, and administrative
    		        1,009,000    3,180,000                                       
      income from operations
    		            -6,089,000                                       
      gain upon extinguishment of payroll protection program loan
    		                                                   
      interest
    		            -17,000                                       
      non-operating income
    		        483,000                                           
      income before income taxes
    		            -5,619,000                                       
      income taxes
    		                                                   
      basic and diluted net income per share
    		                                                   
      weighted-average shares outstanding – basic and diluted
    		        48,442,861                                           
      anti-dilutive stock options, restricted stock units, performance stock units, and common stock warrants
    		        15,960,659                                           
      management fees
    		                                                   
      non-operating expenses
    		            487,000                                       
      basic and diluted net loss per share
    		            -0.13                                       
      weighted-average shares outstanding - basic and diluted
    		            42,020,090                                       
      anti-dilutive stock options, restricted stock units, and performance stock units
    		            16,276,362                                       
      other comprehensive income that will not be reclassified subsequently to income or loss
    		                                                   
      commodity derivative contracts
    		                                                   
      other comprehensive income that will be reclassified subsequently to income or loss
    		                                                   
      royalty expenses
    		                              -720,000 -739 -868,000 -559,000 -579,000 -883,000 -2,619,000 -569,000  -512,000 -574,000 -571,000 -1,604,000 -311,000 -291,000 -433,000 -1,000  -334,000 -392,000 -427,000 
      other operating income and expenses
    		                                   -94,000 -85,000 54,000  337,000 -99,000           
      € in thousands
    		                                                   
      segment revenues and other income
    		                                      450,000             
      inter-segment revenues
    		                                      -78,000             
      external revenues and other income
    		                                      372,000             
      royalties and other operating income and expenses
    		                                      -70,000             
      operating income before tax
    		                                      -5,441,000             
      net income attributable to shareholders of cellectis
    		                                      -5,604,000             
      adjustment of share-based compensation
    		                                      1,548,000             
      adjusted net income attributable to shareholders of cellectis
    		                                      -4,056,000             
      depreciation and amortization
    		                                      -248,000             
      additions to tangible and intangible assets
    		                                      558,000             
      basic earnings attributable to shareholders of cellectis per share
    		                                        -0.53 -0.35 -0.343 -0.36 -18 -84 23  -0.36 -63  
      diluted earnings attributable to shareholders of cellectis per share
    		                                        -0.53 -0.35 -0.343 -0.36 -18 -84 23     
      other operating expenses
    		                                         -218,000 -218,000 -10,000  -199,000 -2,000  -37,000 -285,000 -112,000 
      operating expenses and other operating income
    		                                                   
      redundancy plan
    		                                          750 3,000  1,000 -10,000  24,000 28,000 207,000 
      loss from discontinued operations
    		                                                   
      basic / diluted earnings per share attributable to shareholders of cellectis
    		                                                   
      basic earnings per share
    		                                                  0.23 
      diluted earnings per share
    		                                                  0.23 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2025-11-07 2025-09-30 2025-08-04 2025-06-30 2025-05-12 2025-03-31 2024-12-31 2024-11-04 2024-09-30 2024-08-06 2024-06-30 2024-03-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-11-03 2022-09-30 2022-08-04 2022-06-30 2022-05-12 2022-05-05 2022-03-31 2022-03-03 2021-12-31 2021-11-04 2021-09-30 2021-08-05 2021-06-30 2021-05-06 2021-03-31 2020-12-31 2020-11-05 2020-09-30 2020-08-05 2020-06-30 2020-05-06 2020-03-31 2020-03-04 2019-12-31 2019-11-06 2019-09-30 2019-08-06 2019-05-07 2019-03-31 2019-03-11 2018-12-31 2018-11-13 2018-09-30 2018-08-01 2018-06-30 2018-05-07 2018-03-31 2018-03-12 2017-12-31 2017-11-13 2017-09-30 2017-08-02 2017-06-30 2017-05-09 2017-03-31 2017-03-06 2016-12-31 2016-11-22 2016-09-30 2016-09-08 2016-06-30 2016-05-11 2016-03-31 2016-03-14 2015-12-31 2015-11-16 2015-09-30 2015-09-08 2015-06-30 2015-06-09 2015-03-31 2014-12-31 
                                                                                    
        assets
      		                                                                              
        non-current assets
      		                                                                              
        intangible assets
      		845,000 845,000 1,153,000 1,153,000 242,000 242,000 1,116,000 691,000 691,000 653,000 653,000 677,000 662,000 695,000 713,000 718,000 1,511,000 1,511,000 1,584,000 1,584,000 1,000   1,854,000 1,854,000 2,551,000 2,551,000 1,584,000 1,584,000 1,604,000 1,604,000 1,584,000 1,074,000 1,074,000 1,071,000 1,071,000 1,094,000 1,094,000 1,000 1,268,000 1,000 1,268,000 1,268,000 1,000 1,000 1,000 1,268,000 1,352,000 1,352,000 1,386,000 1,386,000 1,505,000 1,505,000 1,000 1,431,000 1,000 1,000 1,213,000 1,213,000 1,000 1,000 1,000 1,274,000 1,000 1,000 1,268,000 1,268,000 1,000 1,000 956,000 956,000 955,000 955,000 966,000 966,000    
        property, plant and equipment
      		41,198,000 41,198,000  42,790,000 44,451,000 44,451,000 45,895,000 48,956,000 48,956,000 50,370,000 50,370,000 52,051,000 56,774,000                                                                  
        right-of-use assets
      		25,512,000 25,512,000 27,383,000 27,383,000 28,482,000 28,482,000 29,968,000 32,225,000 32,225,000 33,671,000 33,671,000 35,787,000 39,146,000 41,457,000 43,436,000 44,275,000 58,112,000 58,112,000 61,086,000 61,086,000 67,000   69,423,000 69,423,000 71,899,000 71,899,000 74,050,000 74,050,000 71,213,000 71,213,000 73,845,000 64,313,000 64,313,000 63,669,000 63,669,000 47,814,000 47,814,000   46,000   36,000 36,000                                  
        non-current financial assets
      		35,736,000 35,736,000 35,491,000 35,491,000 5,262,000 5,262,000 7,521,000 7,651,000 7,651,000 16,650,000 16,650,000 7,870,000 16,624,000 13,006,000 8,185,000 8,791,000 8,926,000 8,926,000 9,093,000 9,093,000 6,000    6,524,000                                                      
        other non-current assets
      		18,179,000 18,179,000 16,127,000 16,127,000 13,443,000 13,443,000 11,594,000 11,120,000 11,120,000             175,000 175,000                                                        
        deferred tax assets
      		382,000 382,000 382,000 382,000 382,000 382,000 382,000 803,000 803,000                                                                      
        total non-current assets
      		121,852,000 121,852,000 123,326,000 123,326,000 92,262,000 92,262,000 96,476,000 101,445,000 101,445,000 101,344,000 101,344,000 96,386,000 113,205,000 114,389,000 114,042,000 117,406,000 139,307,000 139,307,000 145,716,000 145,716,000 152,000   156,647,000 156,647,000 177,037,000 177,037,000 177,214,000 177,214,000 170,325,000 170,325,000 154,109,000 139,239,000 139,239,000 124,769,000 124,769,000 93,204,000 93,204,000 13,000 13,199,000 69,000 13,199,000 13,199,000 52,000 52,000 13,000 13,199,000 10,308,000 10,308,000 9,490,000 9,490,000 10,090,000 10,090,000 9,000 9,661,000 10,000 10,000 17,515,000 17,515,000 18,000 18,000 17,000 17,963,000 16,000 16,000 17,213,000 17,213,000 13,000 13,000 6,000 6,844,000 6,000 6,000 6,755,000 6,755,000 8,250,000 8,250,000  
        current assets
      		                                                                              
        trade receivables
      		8,056,000 8,056,000 8,776,000 8,776,000 7,870,000 7,870,000 6,714,000 11,180,000 11,180,000 9,741,000 9,741,000 16,036,000 393,000 422,000 1,120,000 772,000 802,000 802,000 2,602,000 2,602,000 21,000   20,361,000 20,361,000 349,000 349,000 3,878,000 3,878,000 6,385,000 6,385,000 5,171,000 4,036,000 4,036,000 3,976,000 3,976,000 3,003,000 3,003,000 2,000 2,971,000 8,000 2,971,000 2,971,000 2,000 2,000 2,000 2,971,000 1,813,000 1,813,000 2,486,000 2,486,000 3,419,000 3,419,000 2,000 2,753,000 2,000 2,000 4,346,000 4,346,000 5,000 5,000 3,000 3,441,000 11,000 11,000 13,816,000 13,816,000 5,000 5,000 6,000 6,035,000 1,000 1,000 3,393,000 3,393,000    
        subsidies receivables
      		16,411,000 16,411,000 16,382,000 16,382,000 15,117,000 15,117,000 14,521,000 15,661,000 15,661,000 14,958,000 14,958,000 23,100,000 20,255,000 19,488,000 18,245,000 14,496,000 12,152,000 12,152,000 11,244,000 11,244,000 10,000   9,268,000 9,268,000 7,971,000 7,971,000 5,654,000 5,654,000 12,535,000 12,535,000 10,703,000 8,364,000 8,364,000 5,367,000 5,367,000 11,230,000 11,230,000 17,000 17,173,000 21,000 17,173,000 17,173,000 19,000 19,000 17,000 17,173,000 15,616,000 15,616,000 14,459,000 14,459,000 11,601,000 11,601,000 9,000 9,524,000 16,000 16,000 13,500,000 13,500,000 11,000 11,000 8,000 8,276,000 14,000 14,000 13,324,000 13,324,000 11,000 11,000 9,000 9,102,000 7,000 7,000 5,966,000 5,966,000    
        other current assets
      		4,503,000 4,503,000 7,333,000 7,333,000 5,147,000 5,147,000 5,528,000 6,643,000 6,643,000 7,587,000 7,587,000 5,429,000 8,488,000 7,869,000 9,703,000 9,078,000 8,311,000 8,311,000 7,694,000 7,694,000 7,000   9,665,000 9,665,000 14,753,000 14,753,000 16,733,000 16,733,000 22,257,000 22,257,000 29,643,000 24,872,000 24,872,000 21,786,000 21,786,000 13,969,000 13,969,000 15,000 15,333,000 15,000 15,333,000 15,333,000 14,000 14,000 15,000 15,333,000 15,925,000 15,925,000 16,313,000 16,313,000 16,671,000 16,671,000 13,000 13,713,000 14,000 14,000 14,196,000 14,196,000 11,000 11,000 8,000 8,414,000 7,000 7,000 8,189,000 8,189,000 7,000 7,000 4,000 4,685,000 7,000 7,000 7,100,000 7,100,000 203,157,000 203,157,000  
        current financial assets
      		139,980,000 139,980,000  138,341,000 116,055,000 116,055,000 117,055,000 101,860,000 101,860,000 123,765,000 123,765,000 90,128,000  1,120,000 4,647,000 7,907,000 21,359,000  24,186,000 24,186,000     499,000 393,000 393,000  3,393,000  18,438,000 27,091,000  41,242,000 50,378,000 50,378,000 59,005,000 59,005,000  388,000  388,000 388,000    388,000 139,000 139,000 19,872,000 19,872,000 40,700,000 40,700,000  40,602,000        34,714,000   87,724,000 87,724,000            
        cash and cash equivalents
      		52,243,000 52,243,000  59,809,000 127,636,000 127,636,000 143,251,000 159,087,000 159,087,000 149,042,000 149,042,000 122,971,000 67,358,000 84,386,000 83,515,000 89,789,000 97,648,000  129,440,000 129,440,000  17,285,000 17,285,000  185,636,000 210,709,000 210,709,000  248,226,000  207,457,000 241,148,000  260,941,000 260,710,000 260,710,000 287,133,000 287,133,000  451,501,000  451,501,000 451,501,000    451,501,000 475,775,000 475,775,000 471,215,000 471,215,000 241,363,000 241,363,000  256,380,000        241,502,000   181,996,000 181,996,000   314,000 314,238,000 279,000 279,000 283,892,000 283,892,000 118,387,000 118,387,000  
        total current assets
      		221,193,000 221,193,000 230,641,000 230,641,000 271,825,000 271,825,000 287,069,000 294,431,000 294,431,000 305,803,000 305,803,000 258,073,000 96,494,000 113,285,000 117,231,000 122,043,000 140,272,000 140,272,000 175,167,000 175,167,000 195,000 18,973,000 18,973,000 225,429,000 225,429,000 235,849,000 235,849,000 280,352,000 280,352,000 272,387,000 272,387,000 315,362,000 345,718,000 345,718,000 347,927,000 347,927,000 377,931,000 377,931,000 487,000 487,641,000 410,000 487,641,000 487,641,000 459,000 459,000 487,000 487,641,000 509,491,000 509,491,000 524,576,000 524,576,000 313,958,000 313,958,000 323,000 323,221,000 338,000 338,000 269,771,000 269,771,000 286,000 286,000 296,000 296,459,000 297,000 297,000 305,173,000 305,173,000 301,000 301,000 334,000 334,218,000 295,000 295,000 300,528,000 300,528,000 331,516,000 331,516,000  
        total assets
      		343,045,000 343,045,000 353,966,000 353,966,000 364,086,000 364,086,000 383,544,000 395,876,000 395,876,000 407,147,000 407,147,000 354,459,000 209,700,000 227,674,000 251,408,000 261,216,000 279,580,000 279,580,000 320,883,000 320,883,000 347,000 38,345,000 38,345,000 382,076,000 382,076,000 412,886,000 412,886,000 457,565,000 457,565,000 442,712,000 442,712,000 469,471,000 484,957,000 484,957,000 472,696,000 472,696,000 471,135,000 471,135,000 500,000 500,840,000 480,000 500,840,000 500,840,000 511,000 511,000 500,000 500,840,000 519,799,000 519,799,000 534,066,000 534,066,000 324,048,000 324,048,000 332,000 332,882,000 349,000 349,000 287,286,000 287,286,000 304,000 304,000 314,000 314,422,000 314,000 314,000 322,387,000 322,387,000 314,000 314,000 341,000 341,062,000 302,000 302,000 307,283,000 307,283,000 339,766,000 339,766,000 167,077,000 
        liabilities
      		                                                                              
        shareholders’ equity
      		                                                                              
        share capital
      		5,902,000 5,902,000 5,902,000 5,902,000 5,900,000 5,900,000 5,889,000 5,906,000 5,906,000 5,897,000 5,897,000 4,376,000 3,492,000 3,491,000 3,487,000 2,955,000 2,949,000 2,949,000 2,946,000 2,946,000 2,000   2,945,000 2,945,000 2,946,000 2,946,000 2,947,000 2,947,000 2,801,000 2,801,000 2,785,000 2,768,000 2,768,000 2,768,000 2,768,000 2,767,000 2,767,000 2,000 2,765,000 2,000 2,765,000 2,765,000 2,000 2,000 2,000 2,765,000 2,765,000 2,765,000 2,764,000 2,764,000 2,374,000 2,374,000 2,000 2,367,000 2,000 2,000 1,793,000 1,793,000 1,000 1,000 1,000 1,767,000 1,000 1,000 1,767,000 1,767,000 1,000 1,000 1,000 1,759,000 1,000 1,000 1,753,000 1,753,000    
        premiums related to the share capital
      		435,162,000 435,162,000 433,549,000 433,549,000 495,266,000 495,266,000 494,288,000 607,153,000 607,153,000 606,146,000 606,146,000 523,596,000 473,325,000 476,224,000 608,086,000 583,122,000 579,047,000 579,047,000 567,284,000 567,284,000 937,000   934,696,000 934,696,000 925,290,000 925,290,000 920,591,000 920,591,000 869,696,000 869,696,000 863,912,000 851,348,000 851,348,000 849,322,000 849,322,000 846,839,000 846,839,000 828,000 828,525,000 839,000 828,525,000 828,525,000 831,000 831,000 828,000 828,525,000 823,353,000 823,353,000 816,363,000 816,363,000 625,634,000 625,634,000 614,000 614,037,000 604,000 604,000 496,752,000 496,752,000 485,000 485,000 473,000 473,306,000 460,000 460,000 448,388,000 448,388,000 434,000 434,000 420,000 420,682,000 405,000 405,000 396,141,000 396,141,000    
        currency translation adjustment
      		-32,725,000 -32,725,000 -33,885,000 -33,885,000 -37,271,000 -37,271,000 -39,537,000 -35,154,000 -35,154,000 -38,077,000 -38,077,000 -37,243,000 -37,505,000 -37,050,000 -28,542,000 -28,605,000 -35,434,000 -35,434,000 -29,626,000 -29,626,000 -21,000   -18,021,000 -18,021,000 -14,345,000 -14,345,000 -9,602,000 -9,602,000 -12,363,000 -12,363,000 -4,089,000 -13,556,000 -13,556,000 -23,730,000 -23,730,000 -29,254,000 -29,254,000 -16,000 -16,668,000 -30,000 -16,668,000 -16,668,000 -22,000 -22,000 -16,000 -16,668,000 -13,561,000 -13,561,000 -11,534,000 -11,534,000 6,097,000 6,097,000 1,000 1,978,000 -530,000 -530,000 -3,030,000 -3,030,000 1,000 1,000 2,000 2,501,000 -1,000 -1,000 -1,510,000 -1,510,000 -3,000 -3,000 -1,000 -1,631,000 -2,000 -2,000 -1,491,000 -1,491,000    
        retained earnings
      		-266,586,000 -266,586,000 -266,592,000 -266,592,000 -329,563,000 -329,563,000 -292,846,000 -405,798,000 -405,798,000 -405,729,000 -405,729,000 -405,808,000 -304,994,000 -305,392,000 -439,220,000 -333,365,000 -330,595,000 -330,595,000 -320,812,000 -320,812,000 -696,000   -584,129,000 -584,129,000 -586,723,000 -586,723,000 -586,284,000 -586,284,000 -586,339,000 -586,339,000 -505,961,000 -508,586,000      -326,000  -406,000   -405,000 -405,000 -326,000 -326,628,000 -326,484,000 -326,484,000 -326,856,000 -326,856,000 -352,969,000 -352,969,000 -251,000 -251,927,000 -251,000 -251,000 -218,496,000 -218,496,000 -218,000 -218,000 -157,000 -157,695,000 -158,000 -158,000 -157,828,000 -157,828,000 -157,000 -157,000 -137,000 -137,188,000 -137,000 -137,000 -137,139,000 -137,139,000    
        net income
      		-41,275,000 -41,275,000 -41,863,000 -41,863,000 -18,128,000 -18,128,000 -36,761,000 -42,683,000 -42,683,000 -19,627,000 -19,627,000 5,643,000 -58,197,000 -40,715,000 -30,074,000 -106,139,000 -79,326,000 -79,326,000 -50,858,000 -50,858,000 -31,000   -114,197,000 -114,197,000 -89,201,000 -89,201,000 -51,787,000 -51,787,000 -11,868,000 -11,868,000 -81,074,000 -41,605,000 -41,605,000 -12,221,000 -12,221,000 20,081,000 20,081,000 -78,000 -78,693,000 -64,000 -78,693,000 -78,693,000 -15,000 -15,000 -78,000 -78,693,000 -55,425,000 -55,425,000 -32,422,000 -32,422,000 -25,438,000 -25,438,000 -99,000 -99,368,000 -72,000 -72,000 -42,653,000 -42,653,000 -18,000 -18,000 -60,000 -60,776,000 -48,000 -48,000 -35,719,000 -35,719,000 -29,000 -29,000 -20,000 -20,544,000 -28,000 -28,000 -16,020,000 -16,020,000    
        total shareholders’ equity - group share
      		100,478,000 100,478,000 97,111,000 97,111,000 116,204,000 116,204,000 131,033,000 129,424,000 129,424,000 148,610,000 148,610,000 90,566,000 76,123,000 96,558,000 113,735,000 117,968,000 136,641,000 136,641,000 168,933,000 168,933,000 191,000   221,293,000 221,293,000 237,967,000 237,967,000 275,864,000 275,865,000 261,926,000 261,926,000 275,573,000 290,369,000  307,606,000 307,606,000 331,843,000 331,843,000 409,000 409,301,000 340,000 409,301,000 409,301,000 391,000 391,000 409,000 409,301,000   447,728,000 447,728,000 255,324,000 255,324,000 266,000  282,000 282,000 234,168,000 234,168,000 251,000 251,000 258,000  253,000 253,000   245,000 245,000 262,000  239,000 239,000 243,056,000 243,056,000 261,877,000 261,877,000  
        total shareholders’ equity
      		100,478,000 100,478,000 97,111,000 97,111,000 116,204,000 116,204,000 131,033,000 129,424,000 129,424,000 148,610,000 148,610,000 90,566,000 76,123,000 96,558,000 120,489,000 125,941,000 145,612,000 145,612,000 180,522,000 180,522,000 203,000   236,474,000 236,474,000 262,147,000 262,147,000 302,323,000 302,323,000 289,744,000 289,744,000 308,846,000 326,210,000 326,210,000 345,059,000 345,059,000 370,588,000 370,588,000 450,000 450,272,000 381,000 450,272,000 450,272,000 432,000 432,000 450,000 450,272,000 471,320,000 471,320,000 488,774,000 488,774,000 276,738,000 276,738,000 285,000 285,904,000 300,000 300,000 237,285,000 237,285,000 253,000 253,000 260,000 260,574,000 255,000 255,000 256,024,000 256,024,000 245,000 245,000 263,000 263,619,000 239,000 239,000 243,219,000 243,219,000 260,856,000 260,856,000 72,272,000 
        non-current liabilities
      		                           948,000  1,109,000                                                 
        non-current financial liabilities
      		63,399,000 63,399,000 55,856,000 55,856,000 51,037,000 51,037,000 50,882,000 61,575,000 61,575,000 58,348,000 58,348,000 62,618,000 43,248,000 40,270,000 19,625,000 20,531,000 14,699,000 14,699,000 15,636,000 15,636,000 18,000   20,030,000 20,030,000 22,767,000 22,767,000 23,475,000 23,475,000 27,990,000 27,990,000 28,836,000 31,473,000 31,473,000 6,640,000 6,640,000   1,000       1,000 1,018,000 209,000 209,000 231,000 231,000 265,000 265,000 13,000 13,000 17,000 17,000 18,000 18,000 21,000 21,000 28,000 28,000 37,000 37,000 38,000 38,000            
        non-current lease debts
      		29,252,000 29,252,000 32,264,000 32,264,000 33,138,000 33,138,000 34,245,000 36,683,000 36,683,000 38,362,000 38,362,000 40,587,000 43,816,000 46,157,000 48,285,000 49,358,000 63,592,000 63,592,000 66,591,000 66,591,000 69,000   71,526,000 71,526,000 73,730,000 73,730,000 75,763,000 75,763,000 73,398,000 73,398,000 75,764,000 67,357,000 67,357,000 64,864,000 64,864,000 48,699,000 48,699,000  1,018,000 44,000 1,018,000 1,018,000 30,000 30,000                                  
        non-current provisions
      		1,339,000 1,339,000 1,303,000 1,303,000 1,139,000 1,139,000 1,115,000 2,427,000 2,427,000 2,194,000 2,194,000 2,241,000 2,560,000 2,641,000 2,540,000 2,390,000 2,646,000 2,646,000 2,852,000 2,852,000 3,000   4,073,000 4,073,000 3,851,000 3,851,000 3,610,000 3,610,000 3,549,000 3,549,000 4,010,000 3,303,000 3,303,000 3,080,000 3,080,000 2,841,000 2,841,000 2,000 2,681,000 2,000 2,681,000 2,681,000 2,000 2,000 2,000 2,681,000 2,907,000 2,907,000 3,054,000 3,054,000 3,307,000 3,307,000 3,000 3,430,000 697,000 697,000 571,000 571,000 551,000 551,000 532,000 532,000 581,000 581,000 565,000 565,000 454,000 454,000 437,000 437,000 375,000 375,000 393,000 393,000    
        total non-current liabilities
      		93,990,000 93,990,000 89,424,000 89,424,000 85,314,000 85,314,000 86,241,000 100,802,000 100,802,000 98,904,000 98,904,000 105,446,000 89,625,000 89,068,000 70,450,000 72,279,000 80,937,000 80,937,000 85,079,000 85,079,000 91,000   96,254,000 96,254,000 101,136,000 101,136,000 103,797,000 103,797,000 106,047,000 106,047,000 108,610,000 102,134,000 102,134,000 74,585,000 74,585,000 51,540,000 51,540,000 3,000 3,699,000 47,000 3,699,000 3,699,000 32,000 32,000 3,000 3,699,000 3,116,000 3,116,000 3,285,000 3,285,000 3,572,000 3,572,000 3,000 3,443,000 714,000 714,000 589,000 589,000 572,000 572,000 560,000 560,000 619,000 619,000 603,000 603,000 509,000 509,000 503,000 503,000 449,000 449,000 484,000 484,000 528,000 528,000  
        current liabilities
      		                                                                              
        current financial liabilities
      		18,240,000 18,240,000 18,230,000 18,230,000 16,786,000 16,786,000 16,134,000 5,350,000 5,350,000 5,119,000 5,119,000 5,174,000 5,058,000 5,185,000 5,188,000 5,088,000 10,379,000 10,379,000 11,310,000 11,310,000 12,000   2,354,000 2,354,000              333,000       333,000 333,000 277,000 277,000 772,000 772,000 82,000 82,000 21,000 21,000 29,000 29,000 61,000 61,000 379,000 379,000 1,000 1,641,000 1,000 1,000 2,173,000 2,173,000            
        current lease debts
      		8,331,000 8,331,000 7,477,000 7,477,000 7,862,000 7,862,000 8,385,000 8,508,000 8,508,000 8,357,000 8,357,000 8,404,000 8,203,000 8,270,000 8,181,000 7,872,000 7,971,000 7,971,000 8,091,000 8,091,000 8,000   8,329,000 8,329,000 8,079,000 8,079,000 7,691,000 7,691,000 6,985,000 6,985,000 6,696,000 4,331,000 4,331,000 3,777,000 3,777,000 1,342,000 1,342,000  333,000 2,000 333,000 333,000 5,000 5,000                                  
        trade payables
      		16,095,000 16,095,000 17,522,000 17,522,000 17,209,000 17,209,000 18,664,000 18,511,000 18,511,000 18,213,000 18,213,000 16,051,000 20,476,000 19,229,000 22,324,000 21,456,000 22,353,000 22,353,000 24,159,000 24,159,000 20,000   23,762,000 23,762,000 22,809,000 22,809,000 28,254,000 28,254,000 24,682,000 24,682,000 24,609,000 35,003,000 35,003,000 32,674,000 32,674,000 26,873,000 26,873,000 15,000 15,883,000 19,000 15,883,000 15,883,000 15,000 15,000 15,000 15,883,000 15,597,000 15,597,000 12,734,000 12,734,000 11,254,000 11,254,000 9,000 9,460,000 12,000 12,000 15,040,000 15,040,000 12,000 12,000 9,000 9,223,000 9,000 9,000 11,324,000 11,324,000 7,000 7,000 6,000 6,611,000 6,000 6,000 5,348,000 5,348,000    
        deferred income and contract liabilities
      		94,008,000 94,008,000  113,379,000 113,304,000 113,304,000 112,161,000 122,006,000 122,006,000 117,754,000 117,754,000 120,556,000                                                                   
        current provisions
      		1,082,000 1,082,000 875,000 875,000 843,000 843,000 828,000 899,000 899,000 884,000 884,000 960,000 946,000 1,029,000 1,011,000 477,000 425,000 425,000 440,000 440,000 578,000   871,000 871,000 4,190,000 4,190,000 1,397,000 1,397,000 1,126,000 1,126,000 1,131,000 1,109,000 1,109,000 1,619,000 1,619,000 3,260,000 3,260,000 1,000 1,530,000 1,000 1,530,000 1,530,000 1,000 1,000 1,000 1,530,000 1,503,000 1,503,000 1,394,000 1,394,000 1,807,000 1,807,000 1,000 1,427,000 923,000 923,000 382,000 382,000 563,000 563,000 563,000 563,000 467,000 467,000 847,000 847,000 1,000 1,000 921,000 953,000 547,000 547,000 444,000 444,000    
        other current liabilities
      		10,820,000 10,820,000 9,949,000 9,949,000 6,565,000 6,565,000 10,097,000 10,376,000 10,376,000 9,184,000 9,184,000 7,165,000 9,153,000 8,093,000 6,094,000 13,179,000 11,582,000 11,582,000 10,884,000 10,884,000 9,000 435,000 435,000 13,731,000 13,731,000 14,024,000 14,024,000 13,681,000 13,681,000 13,865,000 13,865,000 19,127,000 15,731,000 15,731,000 14,499,000 14,499,000 16,990,000 16,990,000 8,000 8,369,000 7,000 8,369,000 8,369,000 4,000 4,000 8,000 8,369,000 7,734,000 7,734,000 6,709,000 6,709,000 5,489,000 5,489,000 6,000 6,570,000 5,000 5,000 5,323,000 5,323,000 4,000 4,000 4,000 4,930,000 5,000 5,000 6,796,000 6,796,000 7,000 7,000 12,000 12,697,000 8,000 8,000 5,217,000 5,217,000    
        total current liabilities
      		148,577,000 148,577,000 167,432,000 167,432,000 162,569,000 162,569,000 166,269,000 165,650,000 165,650,000 159,633,000 159,633,000 158,447,000 43,953,000 42,047,000 43,140,000 48,131,000 53,030,000 53,030,000 55,282,000 55,282,000 52,000 9,520,000 9,520,000 49,348,000 49,348,000 49,603,000 49,603,000 51,446,000 51,446,000 46,922,000 46,922,000 52,015,000 56,613,000 56,613,000 53,052,000 53,052,000 49,008,000 49,008,000 46,000 46,869,000 51,000 46,869,000 46,869,000 47,000 47,000 46,000 46,869,000 45,362,000 45,362,000 42,008,000 42,008,000 43,736,000 43,736,000 43,000 43,534,000 48,000 48,000 49,412,000 49,412,000 50,000 50,000 53,000 53,288,000 58,000 58,000 65,760,000 65,760,000 68,000 68,000 76,000 76,940,000 62,000 62,000 63,580,000 63,580,000 78,381,000 78,381,000 90,894,000 
        total liabilities
      		242,567,000 242,567,000  256,855,000 247,883,000 247,883,000 252,511,000 266,452,000 266,452,000 258,537,000 258,537,000 263,893,000          23,424,000 23,424,000                                                        
        total liabilities and shareholders’ equity
      		343,045,000 343,045,000 353,966,000 353,966,000 364,086,000 364,086,000 383,544,000 395,876,000 395,876,000 407,147,000 407,147,000 354,459,000 209,700,000 227,674,000 251,408,000 261,216,000 279,580,000 279,580,000 320,883,000 320,883,000 347,000   382,076,000 382,076,000 412,886,000 412,886,000 457,565,000 457,565,000 442,712,000 442,712,000 469,471,000 484,957,000 484,957,000 472,696,000 472,696,000 471,135,000 471,135,000 500,000 500,840,000 480,000 500,840,000 500,840,000 511,000 511,000 500,000 500,840,000 519,799,000 519,799,000 534,066,000 534,066,000 324,048,000 324,048,000 332,000 332,882,000 349,000 349,000 287,286,000 287,286,000 304,000 304,000 314,000 314,422,000 314,000 314,000 322,387,000 322,387,000 314,000 314,000 341,000 341,062,000 302,000 302,000 307,283,000 307,283,000 339,766,000 339,766,000  
        property, plant, and equipment
      		  42,790,000           59,231,000 61,708,000 63,621,000 70,759,000 70,759,000 73,953,000 73,953,000 76,000   78,846,000 78,846,000 80,542,000 80,542,000 79,478,000 79,478,000 75,403,000 75,403,000 71,673,000 64,071,000 64,071,000 52,653,000 52,653,000 36,811,000 36,811,000 10,000 10,041,000 16,000 10,041,000 10,041,000 9,000 9,000 10,000 10,041,000 8,299,000 8,299,000 7,437,000 7,437,000 7,688,000 7,688,000 7,000 7,226,000 8,000 8,000 15,466,000 15,466,000 16,000 16,000 16,000 16,033,000 15,000 15,000 15,196,000 15,196,000 11,000 11,000 5,000 5,043,000 4,000 4,000 5,125,000 5,125,000    
        cash and cash equivalent and current financial assets
      		  198,151,000               119,008,000   155,000   186,135,000    251,619,000  225,895,000   302,184,000      451,000  362,000   421,000 421,000 451,000        296,000  304,000 304,000 237,000 237,000 258,000 258,000 276,000  263,000 263,000              
        non-controlling interests
      		              6,754,000 7,973,000 8,971,000 8,971,000 11,588,000 11,588,000 12,000   15,181,000 15,181,000 24,180,000 24,180,000 26,458,000 26,458,000 27,818,000 27,818,000 33,273,000 35,841,000 35,841,000 37,453,000 37,453,000 38,744,000 38,744,000 40,000 40,970,000 41,000 40,970,000 40,970,000 41,000 41,000 40,000 40,970,000 40,672,000 40,672,000 41,046,000 41,046,000 21,414,000 21,414,000 19,000 19,113,000 17,000 17,000 3,118,000 3,118,000 1,000 1,000 1,000 1,779,000 1,000 1,000 1,166,000 1,166,000 829,000 829,000 725,000 725,000 262,000 262,000 163,000 163,000 -1,020,000 -1,020,000  
        deferred revenues and deferred income
      		  113,379,000               320,000   581,000   301,000    423,000  264,000   440,000      20,000  19,000   20,000 20,000 20,000  20,252,000 20,252,000 20,400,000 20,400,000 25,104,000 25,104,000 26,000 26,056,000 29,000 29,000 28,605,000 28,605,000 33,000 33,000 36,000 36,931,000 41,000 41,000 44,620,000 44,620,000 50,000 50,000 54,000 54,758,000 43,000 43,000 49,472,000 49,472,000    
        deferred tax liabilities
      		       118,000 118,000                                                                      
        current deferred tax assets
      		         710,000 710,000 409,000                                                                   
        non-current deferred tax liabilities
      		                                                                              
        current deferred tax liabilities
      		         122,000 122,000 137,000                                                                   
        total assets held for sale
      		              20,135,000 21,768,000                                                               
        deferred revenues and contract liabilities
      		            117,000 241,000 342,000 59,000 320,000  400,000 400,000     301,000 500,000 500,000  423,000  264,000 452,000  440,000 483,000 483,000 543,000 543,000  20,754,000  20,754,000 20,754,000    20,754,000                                
        total liabilities related to asset held for sale
      		              17,328,000 14,864,000                                                               
        inventories
      		                         1,674,000 1,674,000 2,468,000 2,468,000 5,315,000 5,315,000 1,606,000 6,262,000 6,262,000 5,710,000 5,710,000 3,591,000 3,591,000 275,000 275,000 3,000 275,000 275,000 1,000 1,000 275,000 275,000 223,000 223,000 231,000 231,000 203,000 203,000 250,000 250,000 125,000 125,000 114,000 114,000                    
        other non-current liabilities
      		                     73,000 73,000 626,000 626,000 787,000 787,000  948,000  1,109,000                                                
        these amounts reflect adjustments made in connection with the presentation of the discontinued operation
      		                                                                              
        current assets:
      		                                                                              
        restricted cash
      		                     499,000 499,000                                                        
        prepaid expenses and other current assets
      		                     1,189,000 1,189,000                                                        
        non-current restricted cash
      		                     99,000 99,000                                                        
        land, buildings, and equipment
      		                     5,125,000 5,125,000                                                        
        operating lease right-of-use assets
      		                     13,973,000 13,973,000                                                        
        liabilities and stockholders’ equity
      		                                                                              
        current liabilities:
      		                                                                              
        accounts payable
      		                     1,167,000 1,167,000                                                        
        accrued expenses
      		                     379,000 379,000                                                        
        accrued compensation
      		                     2,209,000 2,209,000                                                        
        due to related parties
      		                     64,000 64,000                                                        
        current portion of financing lease obligations
      		                     290,000 290,000                                                        
        common stock warrants
      		                     4,976,000 4,976,000                                                        
        financing lease obligations
      		                     89,000 89,000                                                        
        operating lease obligations
      		                     13,742,000 13,742,000                                                        
        stockholders’ equity:
      		                                                                              
        common stock, 0.0001 par value...
      		                     5,000 5,000                                                        
        additional paid-in capital
      		                     216,838,000 216,838,000                                                        
        common stock in treasury, at cost; 100,152 shares as of march 31, 2022, and december 31, 2021
      		                     -1,043,000 -1,043,000                                                        
        accumulated deficit
      		                     -200,879,000 -200,879,000                                                        
        total stockholders’ equity
      		                     14,921,000 14,921,000                                                        
        total liabilities and stockholders’ equity
      		                     38,345,000 38,345,000                                                        
        other non-current financial assets
      		                       6,524,000  22,045,000 22,045,000 22,101,000 22,101,000 22,105,000 22,105,000 7,007,000 9,781,000 9,781,000 7,376,000 7,376,000 7,484,000 7,484,000 1,000 1,891,000 5,000 1,891,000 1,891,000 4,000 4,000 1,000 1,891,000 657,000 657,000 667,000 667,000 897,000 897,000 1,000 1,004,000 989,000 989,000 835,000 835,000 886,000 886,000 656,000 656,000 612,000 612,000 749,000 749,000 821,000 821,000 845,000 845,000 492,000 492,000 664,000 664,000    
        retained deficit
      		                                 -508,586,000 -508,533,000 -508,533,000 -508,590,000 -508,590,000  -326,628,000  -326,628,000 -326,628,000                                    
        total shareholders’ equity—group share
      		                                 290,369,000              430,648,000 430,648,000      266,791,000        258,795,000        262,894,000        
        treasury share reserve
      		                                                 -587,000 -587,000 -373,000 -373,000 -297,000 -297,000 -302,000 -302,000 -199,000 -199,000 -159,000 -159,000 -307,000 -307,000 -373,000 -373,000 -239,000 -239,000 -190,000 -190,000 -184,000 -184,000 -340,000 -340,000 -189,000 -189,000    
        (*) the 2019 interim condensed consolidated financial statements have been prepared according to the new ifrs 16 “leases” standard with a new “right-of-use assets” category and an implied significant increase of “lease debts” compared to the previous period (see note 2.2 for discussion of the application of ifrs 16 “lease” at january 1, 2019).cellectis s.a.
      		                                                                              
        inventories and accumulated costs on orders in process
      		                                                           106,000 106,000 112,000 112,000 106,000 106,000 125,000 125,000 103,000 103,000 158,000 158,000 178,000 178,000 178,000 178,000    
        total shareholders’ equity — group share
      		                                                                 254,859,000 254,859,000            
        current financial assets, cash and cash equivalent
      		                                                                   276,000 276,000          
        non-current financial debt
      		                                                                   55,000 55,000 66,000 66,000 74,000 74,000 92,000 92,000    
        current financial debt
      		                                                                   1,000 1,000 1,000 1,921,000 2,000 2,000 3,032,000 3,032,000    
        goodwill
      		                                                                              
        redundancy plan
      		                                                                     32,000  51,000 51,000 66,000 66,000    
        current financial assets and cash and cash equivalents
      		                                                                             136,400,000 
        total non current liabilities
      		                                                                             3,912,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2024-11-04 2024-08-06 2022-08-04 2022-05-05 2022-03-31 2021-06-30 2021-05-06 2020-11-05 2020-08-05 2020-05-06 2019-09-30 2019-08-06 2019-05-07 2018-11-13 2018-08-01 2018-05-07 2017-08-02 2017-05-09 2016-11-22 2016-09-08 2016-05-11 2015-09-08 
                              
          cash flows from operating activities
        		                      
          net income for the period
        		-42,683,000 -19,627,000 -54,211,000   -56,956,000 -15,346,000 -51,996,000 -19,290,000 16,602,000        -18,567,000     
          adjustment to reconcile net income to cash from operating activities
        		                      
          adjustments for
        		                      
          amortization and depreciation
        		14,017,000 9,297,000 10,718,000   7,173,000 3,766,000 6,776,000 4,199,000 2,053,000 4,939,000 3,215,000 629,000 1,730,000 1,262,000 629,000 1,191,000 594,000 1,457,000 931,000 477,000 779,000 
          net income (income) on disposals
        		                      
          net financial gain
        		                      
          income tax
        		-514,000 -455,000                     
          expenses related to share-based payments
        		2,283,000 1,717,000 6,285,000   4,020,000 30,000 12,808,000 9,427,000 4,776,000 19,787,000 11,810,000 12,018,000 29,164,000 21,023,000 12,018,000 24,076,000 12,788,000 39,911,000 27,796,000 13,414,000 8,017,000 
          provisions
        		-739,000 -727,000 -113,000   433,000 185,000 -2,426,000 -1,897,000 -308,000 272,000 1,155,000 165,000 -364,000 -342,000 165,000 -146,000 17,000 -441,000 -77,000 99,000 -718,000 
          realized foreign exchange gain
        		254,000 -116,000 -381,000                    
          operating cash flows before change in working capital
        		-33,122,000 -27,933,000 -54,010,000   -63,610,000 -31,219,000 -26,378,000 -4,099,000 21,781,000 -54,071,000 -37,627,000 -11,388,000 -39,679,000 -21,194,000 -11,388,000 -10,944,000 -5,353,000 499,000 -578,000 -5,860,000 -7,285,000 
          decrease (increase) in trade receivables and other current assets
        		                 -4,628,000     
          decrease (increase) in subsidies and tax receivables
        		                      
          increase in trade payables and other current liabilities
        		-899,000 -664,000 -893,000   2,330,000 -2,360,000 4,603,000 3,782,000 659,000 3,950,000 2,370,000 -77,000 7,357,000 3,509,000 -77,000 6,138,000 1,784,000 -4,244,000 -2,213,000 -3,892,000 -3,650,000 
          increase in deferred revenues and contract liabilities
        		6,769,000 8,749,000                     
          change in working capital
        		48,404,000 52,115,000 -6,171,000   10,556,000 -9,710,000 -19,996,000 -16,667,000 -20,323,000 -12,189,000 -5,985,000 -8,591,000 -7,856,000 -11,330,000 -8,591,000 -14,295,000 -9,935,000 -31,305,000 -28,520,000 -13,731,000  
          interest received
        		7,754,000 4,684,000 -848,000   -1,422,000 31,000 3,705,000 2,809,000 753,000 5,844,000 4,146,000 689,000 4,928,000 3,354,000 689,000 519,000  1,540,000 1,188,000 559,000 294,000 
          net cash flows from operating activities
        		23,036,000 28,865,000 -60,181,000   -53,054,000 -40,929,000 -46,374,000 -20,766,000 1,458,000 -66,260,000 -43,613,000 -19,979,000 -47,535,000 -32,523,000 -19,979,000 -25,238,000 -15,288,000 -30,806,000 -29,098,000 -19,591,000 -17,386,000 
          cash flows from investment activities
        		-86,147,000 -108,480,000 -2,537,000                    
          acquisition of intangible assets
        		-65,000 -37,000 -31,000   -23,000 -22,000 -43,000 -41,000 -43,000 -32,000 -29,000 5,000 4,000 1,000 5,000 -83,000 -1,000 -302,000 -428,000 -260,000 -11,000 
          acquisition of property, plant and equipment
        		-2,033,000 -1,256,000 -2,257,000   -13,641,000 -8,191,000 -28,226,000 -21,891,000 -7,912,000 -10,277,000 -4,811,000 -635,000 -2,419,000 -1,186,000 -635,000 -1,183,000 -513,000 -11,259,000 -9,037,000 -6,628,000 -3,140,000 
          sales of non-current financial assets
        		                      
          sale of current financial assets
        		14,756,000                      
          acquisition of non-current financial assets
        		                      
          acquisition of current financial assets
        		-98,803,000                  -78,787,000 -88,213,000 -86,078,000  
          cash flows used in investment activities
        		                      
          cash flows from financing activities
        		                      
          increase in share capital of cellectis after deduction of transaction costs
        		82,823,000 82,823,000                     
          increase in borrowings
        		16,317,000 16,207,000 5,969,000     23,849,000 1,518,000              
          decrease in borrowings
        		-3,954,000 -2,621,000            -65,000 -45,000 -26,000 -18,000 -9,000 -74,000 -58,000 -34,000 -984,000 
          interest paid on financial debt
        		-631,000 -388,000 -178,000                    
          payments on lease debts
        		-8,367,000 -5,615,000 -5,878,000   -6,339,000 -2,237,000 -9,598,000 -3,594,000 -1,899,000 -2,505,000 -1,748,000 -26,000          
          net cash flows from financing activities
        		86,188,000 90,406,000 10,307,000   52,630,000 9,790,000 14,645,000 -1,898,000 -1,899,000 -2,837,000 -1,999,000 3,485,000 236,330,000 234,417,000 3,485,000 1,045,000 265,000 385,000 252,000 257,000 195,346,000 
          increase in cash and cash equivalents
        		23,077,000 10,792,000 -52,411,000   9,518,000 -30,832,000 -83,333,000 -76,546,000 -48,992,000 -102,435,000            
          cash and cash equivalents at the beginning of the period
        		                     112,347,000 
          effect of exchange rate changes on cash and cash equivalents
        		                      
          cash and cash equivalents at the end of the period
        		159,087,000 149,042,000 129,440,000   248,226,000 207,457,000 260,941,000 260,711,000 287,133,000 342,485,000 396,967,000 241,363,000 475,775,000 471,215,000 241,363,000 202,656,000 221,969,000 186,303,000 181,996,000 190,393,000 283,892,000 
          notes
        		                      
          as of january 1, 2024
        		                      
          net income
        		   -5,619,000 -5,619,000             -18,567,000     
          other comprehensive income
        		                      
          total comprehensive income
        		                      
          allocation of prior period loss
        		                      
          capital increase of cellectis
        		                      
          transaction costs related to cellectis' capital increase
        		                      
          derecognition of az sia derivative
        		                      
          vesting of free shares granted to employees and directors
        		                      
          non-cash stock-based compensation expense
        		                      
          other movements
        		                      
          as of september 30, 2024
        		                      
          as of january 1, 2025
        		                      
          as of september 30, 2025
        		                      
          other non-cash items
        		  -460,000   2,000 41,000                
          effect of exchange rate changes on cash
        		-697,000 1,542,000 -3,785,000   -2,439,000 -2,859,000 3,753,000 -3,266,000 -4,397,000 -6,581,000 -1,377,000 2,022,000 -7,080,000 -6,364,000 2,022,000 -11,110,000 -1,868,000 -7,358,000 -5,774,000 -11,550,000 -382,000 
          as of june 30, 2024
        		                      
          as of june 30, 2025
        		                      
          net cash flows used in operating activities
        		                      
          net change in non-current financial assets
        		-3,000 -102,000 -203,000   -93,000 -132,000 -2,480,000 -1,958,000 -1,977,000 -3,604,000 -2,866,000 76,000 223,000 277,000 76,000 -114,000 -148,000 192,000 56,000 4,000 -81,000 
          exercise of share warrants, employee warrants, stock-options and vesting of free-shares
        		                      
          as of march 31, 2024
        		                      
          as of march 31, 2025
        		                      
          net loss for the period from discontinued operations
        		                      
          net income for the period from continuing operations
        		-42,683,000 -19,627,000                     
          intercompany transactions between continuing and discontinued operations
        		                      
          net loss on disposals
        		-62,000  112,000   4,000 57,000 27,000 9,000 9,000 25,000 356,000 20,000 87,000 67,000 20,000 3,000  11,000 11,000  27,000 
          net financial loss
        		-5,677,000 -18,023,000 -15,113,000   -431,000 -4,561,000 4,748,000 645,000 -2,196,000 -11,073,000 -3,848,000 2,130,000 -13,598,000 -10,040,000 2,130,000       
          decrease in trade receivables and other current assets
        		48,305,000 47,929,000 -2,583,000   4,325,000 -1,073,000 -2,741,000 -2,159,000 1,074,000 -8,150,000 -3,436,000 -3,123,000 -1,749,000 -2,695,000 -3,123,000 -6,882,000  -8,076,000 -11,240,000 -2,526,000 1,217,000 
          decrease in subsidies and tax receivables
        		-5,772,000 -3,898,000                     
          net cash flows from operating activities of continuing operations
        		23,036,000 28,865,000                    -17,386,000 
          net cash flows from operating activities of discontinued operations
        		                      
          calyxt’s cash and cash equivalents disposed of
        		                      
          net cash flows from investing activities of continuing operations
        		-86,147,000 -108,480,000 -2,537,000                   -6,032,000 
          net cash flows from investing activities of discontinued operations
        		                      
          net cash flows from financing activities of continuing operations
        		86,188,000 90,406,000                    195,346,000 
          net cash flows from financing activities of discontinued operations
        		                      
          cash and cash equivalents at the beginning of the year
        		136,708,000 136,708,000 185,636,000   241,148,000 241,148,000 340,522,000 340,522,000 340,522,000 451,501,000 451,501,000 256,380,000 256,380,000 256,380,000 256,380,000 241,502,000 241,502,000 314,238,000 314,238,000 314,238,000  
          cash from discontinued operations
        		                      
          cash from continuing operations
        		159,087,000                   181,996,000 190,393,000 283,892,000 
          net income for the period from discontinued operations
        		                      
          sale (acquisition) of current financial assets
        		 -107,085,000 -46,000   23,698,000 8,652,000 -20,856,000 -29,993,000 -38,620,000 -19,840,000 161,000  39,853,000 20,192,000  -2,162,000 -1,982,000     
          interest expense /
        		                      
          interest (paid) / received
        		                 -206,000     
          decrease (increase) in subsidies receivables
        		                 -3,284,000     
          net income for the period of discontinued operations
        		                      
          net income for the period of continuing operations
        		                -42,653,000     -15,850,000 
          increase in deferred income
        		  112,000   -19,000 -179,000 -19,617,000 -19,167,000 -19,114,000 129,000 54,000 -3,619,000 -6,981,000 -7,069,000 -3,619,000 -8,283,000 -3,813,000 -12,846,000 -10,122,000 -4,554,000 -10,114,000 
          *
        		                      
          intangible assets
        		                      
          property, plant, and equipment
        		                      
          right-of-use assets
        		                      
          other non-current assets
        		                      
          other current assets
        		                      
          cash and cash equivalents
        		                      
          total assets held for sale
        		                      
          non-current lease debts
        		                      
          other non-current liabilities
        		                      
          current lease debts
        		                      
          trade payables
        		                      
          other current liabilities
        		                      
          total liabilities related to assets held for sale
        		                      
          net assets held for sale
        		                      
          •
        		                      
          gain upon the forgiveness of the payroll protection program loan
        		     -1,528,000                 
          convertible note received for up-front license fee classified in non-current assets
        		     -14,904,000 -15,423,000                
          decrease (increase) in inventories
        		                 6,000     
          proceeds from the exercise of cellectis stock options
        		                      
          proceeds from the exercise of calyxt stock options
        		                      
          increase in share capital cellectis
        		     46,924,000                 
          increase in share capital calyxt
        		  11,342,000                    
          costs incurred related to calyxt’s follow-on offering
        		  -948,000                    
          as of january 1, 2021
        		                      
          exercise of stock options calyxt
        		                      
          capital increase cellectis
        		                      
          transaction costs
        		                     -16,842,000 
          transaction with subsidiaries
        		                      
          exercise of share warrants, employee warrants, stock-options and free-shares vesting cellectis
        		                      
          as of september 30, 2021
        		                      
          as of january 1, 2022
        		                      
          issuance of calyxt’s common stock and exercise of calyxt’s pre-funded warrants
        		                      
          as of september 30, 2022
        		                      
          decrease in inventories
        		     -866,000 -3,735,000 -3,353,000 -2,813,000 -702,000 -3,105,000 -709,000 54,000 19,000 12,000 54,000 -2,000  52,000 32,000 54,000 -43,000 
          decrease in subsidies receivables
        		  -2,807,000   4,787,000 -2,363,000 1,112,000 3,690,000 -2,239,000 -5,012,000 -4,266,000 -1,826,000 -6,502,000 -5,086,000 -1,826,000 -5,265,000  -6,191,000 -4,978,000 -2,813,000  
          revenue
        		   32,000                   
          cost of goods sold
        		                      
          gross profit
        		   32,000                   
          operating expenses:
        		                      
          research and development
        		   2,941,000                   
          selling, general, and administrative
        		   3,180,000                   
          management fees
        		                      
          total operating expenses
        		   6,121,000              -28,208,000     
          income from operations
        		   -6,089,000                   
          interest
        		   -17,000                   
          non-operating expenses
        		   487,000                   
          income before income taxes
        		   -5,619,000                   
          income taxes
        		                      
          basic and diluted net income per share
        		   -130                   
          weighted-average shares outstanding - basic and diluted
        		   42,020,090,000                   
          anti-dilutive stock options, restricted stock units, and performance stock units
        		   16,276,362,000                   
          calyxt, inc.
        		                      
          consolidated statements of cash flows
        		                      
          operating activities
        		                      
          adjustments to reconcile net income to net cash used by operating activities:
        		                      
          depreciation and amortization
        		   370,000 370,000                  
          stock-based compensation
        		   531,000 531,000                  
          unrealized (gain) loss on mark-to-market of common stock warrants
        		   -435,000 -435,000                  
          changes in operating assets and liabilities:
        		                      
          accounts receivable
        		                      
          due to/from related parties
        		   -108,000 -108,000                  
          inventory
        		                      
          prepaid expenses and other current assets
        		   -110,000 -110,000                  
          accounts payable
        		   -145,000 -145,000                  
          accrued expenses
        		   37,000 37,000                  
          accrued compensation
        		   -313,000 -313,000                  
          other
        		   -612,000 -612,000                  
          net cash used by operating activities
        		   -6,404,000 -6,404,000                  
          investing activities
        		                      
          sales and (purchases) of short-term investments
        		                      
          purchases of land, buildings, and equipment
        		   -545,000 -545,000                  
          net cash (used by) provided by investing activities
        		   -545,000 -545,000                  
          financing activities
        		                      
          proceeds from the issuance of common stock
        		   11,209,000 11,209,000                  
          costs incurred related to the issuance of common stock
        		   -704,000 -704,000                  
          repayments of financing lease obligations
        		   -94,000 -94,000                  
          proceeds from the exercise of stock options
        		                      
          net cash from financing activities
        		   10,411,000 10,411,000                  
          net increase in cash, cash equivalents, and restricted cash
        		   3,462,000 3,462,000                  
          cash, cash equivalents, and restricted cash - beginning of period
        		   14,421,000 14,421,000                  
          cash, cash equivalents, and restricted cash – end of period
        		   17,883,000 17,883,000                  
          foreign exchange gain
        		                      
          as of january 1, 2020
        		                      
          operation between shareholders
        		                      
          exercise of share warrants, employee warrants, stock options and free shares vesting
        		                      
          as of september 30, 2020
        		                      
          reconciliation of net income and of the cash from operating activities
        		                      
          net cash flows from investing activities
        		     9,941,000 307,000 -51,604,000 -53,882,000 -48,552,000 -33,339,000 -7,545,000 -546,000 37,680,000 19,304,000 -546,000 -3,543,000 -2,643,000 -90,156,000 -97,623,000 -92,962,000 -6,032,000 
          proceeds from the exercise of stock options cellectis
        		     11,818,000 11,818,000                
          proceeds from the exercise of stock options calyxt
        		     227,000 209,000                
          proceeds from disposal of property, plant and equipment
        		          414,000  7,000 19,000 20,000 7,000      50,000 
          reconciliation of net income and of the cash from
        		                      
          other non cash items
        		       -20,000  93,000    418,000         
          treasury shares
        		            -76,000 297,000 -291,000 -76,000 108,000 148,000 -189,000 -56,000 -6,000 62,000 
          increase in share capital net of transaction costs
        		       183,000     2,873,000 186,433,000 185,992,000 2,873,000 954,000 126,000 648,000 365,000 298,000  
          shares of calyxt issued to third parties
        		       211,000 179,000   -251,000 714,000 49,665,000 48,761,000 714,000       
          net loss for the period
        		          -73,865,000 -54,461,000 -27,038,000 -62,044,000 -36,518,000 -27,038,000 -42,653,000  -48,309,000 -35,719,000 -29,464,000 -15,850,000 
          reconciliation of net loss and of the cash from operating activities
        		                      
          cash flows from investing activities
        		                      
          shares of calyxt issued to / (purchased from) third parties
        		          -332,000            
          increase in cash
        		           -53,157,000 -17,040,000 226,475,000 221,198,000 -17,040,000 -27,736,000 -17,666,000 -120,577,000 -126,469,000 -112,296,000 171,927,000 
          increase in deferred income and contract liabilities
        		                      
          sale (acquisition) of subsidiaries net of cash disposed of
        		                      
          net loss for the period of discontinued operations
        		                      
          movements in valuation allowances of working capital
        		                      
          net finance expenses
        		                6,067,000 21,000 6,330,000 5,292,000 9,055,000  
          revenues and other income
        		                      
          revenues
        		                 6,328,000     
          other income
        		                 3,334,000     
          total revenues and other income
        		                 9,662,000     
          operating expenses
        		                      
          royalty expenses
        		                 -574,000     
          research and development expenses
        		                 -18,392,000     
          selling, general and administrative expenses
        		                 -9,143,000     
          other operating income and expenses
        		                 -99,000     
          operating income
        		                 -18,546,000     
          financial gain
        		                 -21,000     
          attributable to shareholders of cellectis
        		                 -18,567,000     
          attributable to non-controlling interests
        		                      
          basic / diluted earnings per share attributable to shareholders of cellectis
        		                      
          basic earnings per share
        		                 -530     
          diluted earnings per share
        		                 -530     
          currency translation adjustment
        		                      
          other comprehensive income that will be reclassified subsequently to income or loss
        		                      
          net income on disposals
        		                      
          net finance expenses / revenue
        		                     166,000 
          other items
        		                      
          decrease in current assets
        		                      
          increase in subsidies receivables
        		                     2,489,000 
          increase in current liabilities
        		                      
          change in the working capital
        		                     -10,101,000 
          proceeds from sale of subsidiaries net of cash disposed of
        		                     -2,850,000 
          increase in share capital
        		                     213,110,000 
          increase in cash of continuing operations
        		                      
          increase in cash of discontinued operations
        		                      
          cash and cash equivalents at the end of the year